	US RE50,563 E1
	Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
Michael R. Ruff, Potomac, MD (US)
Assigned to Creative Bio-Peptides, Inc., Potomac, MD (US)
Filed by Creative Bio-Peptides, Inc., Potomac, MD (US)
Filed on Mar. 23, 2022, as Appl. No. 17/701,974.
Application 17/701,974 is a continuation of application No. 17/698,065, filed on Mar. 18, 2022.
Application 17/698,065 is a reissue of application No. 16/177,344, filed on Oct. 31, 2018, granted, now 10,624,945, issued on Apr. 21, 2020.
Application 17/701,974 is a reissue of application No. 16/177,344, filed on Oct. 31, 2018, granted, now 10,624,945, issued on Apr. 21, 2020.
Claims priority of provisional application 62/579,545, filed on Oct. 31, 2017.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/08 (2019.01); A61K 9/20 (2006.01); A61P 25/04 (2006.01); A61K 9/10 (2006.01)

CPC A61K 38/08 (2013.01) [A61P 25/04 (2018.01); A61K 9/10 (2013.01); A61K 9/20 (2013.01)]

8 Claims

[ 11. A method of treating an opioid use disorder in a patient comprising:

administering to the patient a therapeutically effective dose of a pharmaceutical composition comprising an all-D peptide and a pharmaceutically acceptable carrier, wherein the all-D peptide comprises five contiguous amino acids and is at most 8 amino acid residues in length, having the general structure: A-B-C-D-E in which:

A is Ser, Thr, Asn, Glu, or Ile,

B is Ser, Thr, Asp, or Asn,

C is Thr, Ser, Asn, Arg, or Trp,

D is Tyr, and

E is Thr, Ser, Arg, or Gly,

wherein in the all-D peptide, all stereoisomeric amino acids are in the D stereoisomeric configuration, and wherein the pharmaceutical composition acts to treat the opioid use disorder in the patient.]